United States: Wilmerhale Counsels Agios Pharmaceuticals In Exclusive License Agreement With Aurigene Discovery Technologies
Last Updated: May 9 2017

Agios Pharmaceuticals, Inc. and Aurigene Discovery Technologies Limited announced a global license agreement to research, develop and commercialize small molecule inhibitors of an undisclosed cancer metabolism target. Under the terms of the agreement, Agios will conduct pre-clinical studies and, if successful, fund further global research and development, as well as regulatory and commercial activities.

The WilmerHale team counseling Agios Pharmaceuticals included Steven Barrett and Mat Trachok.

Read Agios Pharmaceuticals' press release for more information.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Press Releases from this Firm
Recent Content from this Firm
By Alan Wilson, Jonathan Wolfman
By Ambassador Charlene Barshefsky, Naboth van den Broek, David Ross, Patrick J. McLain, David Horn
By Frederick Saugman
By Bill Warren
By Michael Connor, H. David Gold, Sarah Judkins, Andrew L. Spielman
By Lester Ross, Tingting Liu
By H. David Gold, Rachel Jacobson, Heidi K. Ruckriegle
By Joseph Mueller, Thomas Saunders, Leslie Pearlson
By WilmerHale
By Robert D. Burke, A. William Caporizzo, Julie Hogan Rodgers, Meghan Walsh
Font Size: